Cutrona, Costanza
Pede, Elisa
De Sanctis, Roberto
Coratti, Giorgia
Tiberi, Eloisa
Luciano, Rita
Pera, Maria Carmela
Velli, Chiara
Capasso, Anna
Vento, Giovanni
Romeo, Domenico M.
Pane, Marika
Mercuri, Eugenio
Article History
Received: 8 February 2022
Revised: 6 April 2022
Accepted: 9 April 2022
First Online: 4 May 2022
Change Date: 12 September 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: The study was approved by the ethics committee of our center (Policlinico Agostino Gemelli, Rome).
: Informed consent was obtained from the parents of all participants included in the study.
: Informed consent was obtained from the parents of all participants included in the study.
: De Sanctis R reports personal fees from Biogen S.R.L. Italia, AveXis, and Novartis outside the submitted work; Coratti G reports personal fees from Biogen S.R.L. Italia, Roche, Genesis Pharma, AveXis, Novartis, and Biologix, outside the submitted work; Pera MC reports personal fees from Roche outside the submitted work; Pane M reports personal fees from Biogen S.R.L., PTC, AveXis, Novartis, and Sarepta, outside the submitted work; Mercuri E reports personal fees from AveXis, Novaris, Roche, Biogen S.R.L., PTC Therapeutics, Sarepta, and Santhera, outside the submitted work; Cutrona C, Pede E, Tiberi E, Luciano R, Velli C, Capasso A, Vento G, and Romeo DM have nothing to disclose.